Repurposing of SARS Inhibitors Against COVID 19

24 April 2020, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


Till this date there is no vaccine or drug for coronavirus responsible for COVID-19 which has created a major challenge to stop the spread of disease. Repurposing of a drug could be a solution for this challenge, as many previously available drugs hold great potential to act as a drug molecule. The coronavirus mainly affects the host by binding to its specific receptor with the help of its surface glycoprotein or spike glycoprotein. Thus, interfering this interaction could be a potent mechanism to stop the viral infection and propagation. In this paper, we have discussed about the surface glycoprotein and how previously available drug could be repurposed to act as a potent inhibitor. Homology modelling and docking studies has been mainly done to identify the interaction and binding affinity of previous drugs and how they could act as a potential solution to stop the overall spread of the disease in case of pandemic like COVID-19 where unavailability of specific drug or vaccine is responsible for taking to the lives of many.


Docking approaches


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.